Drug Profile


Alternative Names: INO 8875/trabodenoson; PJ 875/trabodenoson; Trabodenoson/latanoprost

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Prostaglandins; Small molecules
  • Mechanism of Action Adenosine A1 receptor agonists; Gelatinase stimulants; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 22 Jul 2016 Inotek Pharmaceuticals has patent protection for latanoprost/trabodenoson in USA
  • 12 Jul 2016 Inotek Pharmaceuticals initiates a phase II trial for Glaucoma and Ocular hypertension in USA (9199399; NCT02829996)
  • 23 Mar 2016 Inotek plans a phase II trial for Ocular hypertension and Glaucoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top